Harrison Scott T, Poslusney Michael S, Mulhearn James J, Zhao Zhijian, Kett Nathan R, Schubert Jeffrey W, Melamed Jeffrey Y, Allison Timothy J, Patel Sangita B, Sanders John M, Sharma Sujata, Smith Robert F, Hall Dawn L, Robinson Ronald G, Sachs Nancy A, Hutson Pete H, Wolkenberg Scott E, Barrow James C
Department of Medicinal Chemistry, Global Structural Biology, Chemical Modeling and Informatics, and Department of Neuroscience Research, Merck Research Laboratories , Sumneytown Pike, West Point, Pennsylvania 19486, United States.
ACS Med Chem Lett. 2015 Jan 26;6(3):318-23. doi: 10.1021/ml500502d. eCollection 2015 Mar 12.
3-Hydroxy-4-pyridinones and 5-hydroxy-4-pyrimidinones were identified as inhibitors of catechol-O-methyltransferase (COMT) in a high-throughput screen. These heterocyclic catechol mimics exhibit potent inhibition of the enzyme and an improved toxicity profile versus the marketed nitrocatechol inhibitors tolcapone and entacapone. Optimization of the series was aided by X-ray cocrystal structures of the novel inhibitors in complex with COMT and cofactors SAM and Mg(2+). The crystal structures suggest a mechanism of inhibition for these heterocyclic inhibitors distinct from previously disclosed COMT inhibitors.
在一次高通量筛选中,3-羟基-4-吡啶酮和5-羟基-4-嘧啶酮被鉴定为儿茶酚-O-甲基转移酶(COMT)的抑制剂。这些杂环儿茶酚类似物对该酶表现出强效抑制作用,并且与市售的硝基儿茶酚抑制剂托卡朋和恩他卡朋相比,毒性特征有所改善。新型抑制剂与COMT以及辅因子SAM和Mg(2+)形成的X射线共晶体结构有助于该系列化合物的优化。晶体结构表明这些杂环抑制剂的抑制机制与先前公开的COMT抑制剂不同。